Indications for INNOPRAN XL:
≥18yrs: Take once daily at bedtime (10PM). Take consistently with regard to food. Initially 80mg/day, may increase to 120mg/day.
<18yrs: not recommended.
INNOPRAN XL Contraindications:
Cardiogenic shock. Sinus bradycardia, sick sinus syndrome and >1st -degree AV block unless paced. Asthma.
Cardiac ischemia after abrupt discontinuation.
INNOPRAN XL Warnings/Precautions:
Risk of cardiac ischemia after abrupt discontinuation. Bronchospastic disease. Heart failure. Cardiogenic shock. Wolff-Parkinson-White syndrome. Diabetes. May mask signs of hypoglycemia, hyperthyroidism. Surgery. SLE. Musculoskeletal disease. Renal or hepatic impairment. Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers.
INNOPRAN XL Classification:
INNOPRAN XL Interactions:
Potentiated by substrates or inhibitors of CYP2D6 (eg, amiodarone, cimetidine, fluoxetine, paroxetine, quinidine, ritonavir), CYP1A2 (eg, imipramine, ciprofloxacin, theophylline, zolmitriptan), or CYP2C19 (eg, fluconazole), CNS depressants, other antihypertensives, antithyroid drugs, haloperidol, MAOIs, tricyclic antidepressants, alcohol. Antagonized by NSAIDs, aluminum hydroxide; bile acid resins (eg, cholestyramine, colestipol); smoking, chronic alcohol use, and other inducers of CYP2D6, 1A2, or 2C19. Potentiates amiodarone, chlorpromazine, diazepam, lidocaine, bupivacaine, mepivacaine, propafenone, theophylline, thioridazine, warfarin, rizatriptan, zolmitriptan. May increase cardiac effects of calcium channel blockers, digitalis, disopyramide, lidocaine. Bradycardia with catecholamine-depleting drugs. Increased orthostatic hypotension with α-blockers. Caution when withdrawing clonidine. Increased bronchial hyperreactivity with ACEIs. May interfere with glaucoma or thyroid tests. May block epinephrine.
Fatigue, dizziness, constipation, bradycardia, heart failure/block, GI upset, bronchospasm, agranulocytosis, myopathy, myotonia, skin reactions (eg, rash, Stevens-Johnson syndrome, urticaria); rare: SLE, alopecia, impotence.